Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 3, 2010, Pages 242-244

  Rosborough, Terry K ^a   Jacobsen, Jennifer M ^a   Shepherd, Michele F ^a  

^a ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

Chromogenic factor X; Factor II; International Normalized Ratio; Lupus anticoagulant; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10; LUPUS ANTICOAGULANT; PROTHROMBIN; WARFARIN;

ACCURACY; ARTICLE; ASSAY; BLOOD EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOSIS;

ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; FACTOR X; HUMANS; LUPUS COAGULATION INHIBITOR; PROTHROMBIN; THROMBOSIS; WARFARIN;

EID: 77950249879     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833581a3     Document Type: Article

References (9)

1. Baker WF, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin N Am 2008; 22:33-52.
2. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177-185.
3. Trask AS, Gosselin RC, Diaz JA, Dager WE.Warfarin initiation and monitoring with clotting factors II, VII, and X. Ann Pharmacother 2004; 38:251-256.
4. Bardin N, Alessi MC, Dignat-George F, Vague IJ, Sampol J, Harlé JR, Sanmarco M. Does the antiprothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology 2007; 212:557-565.
5. Tincani A, Morozzi G, Afeltra A, Alessandri C, Allegri F, Bistoni O, et al. Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol 2007; 25:268-274.
6. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110:1178-1183.
7. Rosborough TK, Shepherd MF. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 2004; 24:838-842.
8. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48-53.
9. McGlasson DL, Romick BG, Rubal BJ. Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinolysis 2008; 19:513-517.